{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:26:06Z","timestamp":1792513566672,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p><jats:bold>Purpose of review:<\/jats:bold> Mineral and bone disorder (MBD) is a prevalent complication in chronic kidney disease (CKD), significantly impacting overall health with multifaceted implications including fractures, cardiovascular events, and mortality. Despite its pervasive nature, effective treatments for CKD-MBD are lacking, emphasizing the urgency to advance understanding and therapeutic interventions. Bone metabolism intricacies, influenced by factors like 1,25 dihydroxy vitamin D, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF23), along with intrinsic osseous mechanisms, play pivotal roles in CKD. Skeletal abnormalities precede hormonal changes, persisting even with normalized systemic mineral parameters, necessitating a comprehensive approach to address both aspects.<\/jats:p><jats:p><jats:bold>Recent findings:<\/jats:bold> In this review, we explore novel pathways involved in the regulation of systemic mineral bone disease factors, specifically examining anemia, inflammation, and metabolic pathways. Special emphasis is placed on internal bone mechanisms, such as hepatocyte nuclear factor 4\u03b1, transforming growth factor-\u03b21, and sclerostin, which play crucial roles in the progression of renal osteodystrophy.<\/jats:p><jats:p><jats:bold>Summary:<\/jats:bold> Despite advancements, effective treatments addressing CKD-MBD morbidity and mortality are lacking, necessitating ongoing research for novel therapeutic targets.<\/jats:p>","DOI":"10.3389\/fphys.2024.1356069","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T09:21:48Z","timestamp":1709284908000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Bone and bone derived factors in kidney disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Petra","family":"Simic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/sdi.12423","article-title":"Bone disorders in chronic kidney disease: an update in diagnosis and management","volume":"28","author":"Babayev","year":"2015","journal-title":"Semin. Dial."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2215\/CJN.06550810","article-title":"Sclerostin and Dickkopf-1 in renal osteodystrophy","volume":"6","author":"Cejka","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.semnephrol.2018.10.005","article-title":"Fibroblast growth factor 23 and klotho in AKI","volume":"39","author":"Christov","year":"2019","journal-title":"Semin. Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1152\/ajprenal.00359.2016","article-title":"Ironing out the cross talk between FGF23 and inflammation","volume":"312","author":"David","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.kint.2018.02.026","article-title":"Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease","volume":"94","author":"Durlacher-Betzer","year":"2018","journal-title":"Kidney Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.kint.2019.04.009","article-title":"Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation","volume":"96","author":"Egli-Spichtig","year":"2019","journal-title":"Kidney Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Gutierrez","year":"2009","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Gutierrez","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bone.2017.11.015","article-title":"Sclerostin deficiency modifies the development of CKD-MBD in mice","volume":"107","author":"Kaesler","year":"2018","journal-title":"Bone"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.10.001","article-title":"Erratum: kidney disease: improving global outcomes (KDIGO) CKD-MBD update work group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney int suppl. 2017;7:1-59","volume":"7","year":"2011","journal-title":"Kidney Int. Suppl."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1681\/ASN.2016080836","article-title":"Fibroblast growth factor 23 levels associate with AKI and death in critical illness","volume":"28","author":"Leaf","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s12020-022-03199-1","article-title":"Roxadustat improves renal osteodystrophy by dual regulation of bone remodeling","volume":"79","author":"Li","year":"2023","journal-title":"Endocrine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/jbmr.2120","article-title":"Role of TGF-\u03b2 in a mouse model of high turnover renal osteodystrophy","volume":"29","author":"Liu","year":"2014","journal-title":"J. Bone Min. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e159928","DOI":"10.1172\/JCI159928","article-title":"Transcription factor HNF4\u03b12 promotes osteogenesis and prevents bone abnormalities in mice with renal osteodystrophy","volume":"133","author":"Martinez-Calle","year":"2023","journal-title":"J. Clin. Invest."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/jbmr.4003","article-title":"IL-1\u03b2 drives production of FGF-23 at the onset of chronic kidney disease in mice","volume":"35","author":"McKnight","year":"2020","journal-title":"J. Bone Min. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2362.2006.01665.x","article-title":"Vascular calcification and renal osteodystrophy relationship in chronic kidney disease","volume":"36","author":"Moe","year":"2006","journal-title":"Eur. J. Clin. Invest."},{"key":"B19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/jbmr.2372","article-title":"Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy","volume":"30","author":"Moe","year":"2015","journal-title":"J. Bone Min. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e14434","DOI":"10.14814\/phy2.14434","article-title":"Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)","volume":"8","author":"Noonan","year":"2020","journal-title":"Physiol. Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e10464","DOI":"10.1002\/jbm4.10464","article-title":"Characterization of primary cilia in osteoblasts isolated from patients with ADPKD and CKD","volume":"5","author":"Pereira","year":"2021","journal-title":"JBMR Plus"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.bone.2009.08.008","article-title":"Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease","volume":"45","author":"Pereira","year":"2009","journal-title":"Bone"},{"key":"B23","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.bone.2019.07.026","article-title":"Vitamin D sterols increase FGF23 expression by stimulating osteoblast and osteocyte maturation in CKD bone","volume":"127","author":"Pereira","year":"2019","journal-title":"Bone"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.kint.2018.08.011","article-title":"Impaired osteocyte maturation in the pathogenesis of renal osteodystrophy","volume":"94","author":"Pereira","year":"2018","journal-title":"Kidney Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e2022841118","DOI":"10.1073\/pnas.2022841118","article-title":"Orphan nuclear receptor ERR-gamma regulates hepatic FGF23 production in acute kidney injury","volume":"118","author":"Radhakrishnan","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e2214396119","DOI":"10.1073\/pnas.2214396119","article-title":"Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice","volume":"119","author":"Sato","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.kint.2016.03.028","article-title":"Turning over renal osteodystrophy dogma: direct actions of FGF23 on osteoblast \u03b2-catenin pathway","volume":"90","author":"Schiavi","year":"2016","journal-title":"Kidney Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1172\/JCI61405","article-title":"FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality","volume":"122","author":"Shalhoub","year":"2012","journal-title":"J. Clin. Invest."},{"key":"B29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature10152","article-title":"Latent TGF-\u03b2 structure and activation","volume":"474","author":"Shi","year":"2011","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1172\/JCI131190","article-title":"Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney","volume":"130","author":"Simic","year":"2020","journal-title":"J. Clin. Invest."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.kint.2017.11.018","article-title":"Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury","volume":"93","author":"Toro","year":"2018","journal-title":"Kidney Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2215\/CJN.05940611","article-title":"Early skeletal and biochemical alterations in pediatric chronic kidney disease","volume":"7","author":"Wesseling-Perry","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e163627","DOI":"10.1172\/JCI163627","article-title":"A parathyroid hormone\/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis","volume":"133","author":"Yoon","year":"2023","journal-title":"J. Clin. Invest."},{"key":"B34","doi-asserted-by":"publisher","first-page":"6404","DOI":"10.3390\/ijms23126404","article-title":"Inactivation of osteoblast PKC signaling reduces cortical bone mass and density and aggravates renal osteodystrophy in mice with chronic kidney disease on high phosphate diet","volume":"23","author":"Zaloszyc","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1007\/s11255-023-03569-2","article-title":"The WNT\/\u03b2-catenin system in chronic kidney disease-mineral bone disorder syndrome","volume":"55","author":"Zhang","year":"2023","journal-title":"Int. Urol. Nephrol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e164610","DOI":"10.1172\/JCI164610","article-title":"Kidney glycolysis serves as a mammalian phosphate sensor that maintains phosphate homeostasis","volume":"133","author":"Zhou","year":"2023","journal-title":"J. Clin. Invest."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2024.1356069\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T09:21:50Z","timestamp":1709284910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2024.1356069\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":36,"alternative-id":["10.3389\/fphys.2024.1356069"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2024.1356069","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]},"article-number":"1356069"}}